{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:24:00Z","timestamp":1763457840207,"version":"build-2065373602"},"reference-count":139,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Phosphate toxicity is a well-established phenomenon, especially in chronic kidney disease (CKD), where hyperphosphatemia is a frequent occurrence when CKD is advanced. Many therapeutic efforts are targeted at phosphate, and comprise dietary intervention, modifying dialysis schemes, treating uncontrolled hyperparathyroidism and importantly, phosphate binder therapy. Despite all these interventions, hyperphosphatemia persists in many, and its pathological influence is ongoing. In nephrological care, a somewhat neglected aspect of treatment\u2014when attempts fail to lower exposure to a toxin like phosphate\u2014is to explore the possibility of \u201canti-dotes\u201d. Indeed, quite a long list of factors modify, or are mediators of phosphate toxicity. Addressing these, especially when phosphate itself cannot be sufficiently controlled, may provide additional protection. In this narrative overview, several factors are discussed that may qualify as either such a modifier or mediator, that can be influenced by other means than simply lowering phosphate exposure. A wider scope when targeting phosphate-induced comorbidity in CKD, in particular cardiovascular disease, may alleviate the burden of disease that is the consequence of this potentially toxic mineral in CKD.<\/jats:p>","DOI":"10.3390\/toxins11090522","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T11:26:17Z","timestamp":1568028377000},"page":"522","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Modifying Phosphate Toxicity in Chronic Kidney Disease"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4607-9415","authenticated-orcid":false,"given":"Marc","family":"Vervloet","sequence":"first","affiliation":[{"name":"Department of Nephrology and Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Vervloet, M.G., Sezer, S., Massy, Z.A., Johansson, L., Cozzolino, M., Fouque, D., and ERA\u2013EDTA Working Group on Chronic Kidney Disease\u2013Mineral and Bone Disorders and the European Renal Nutrition Working Group (2016). The role of phosphate in kidney disease. Nat. Rev. Nephrol.","key":"ref_1","DOI":"10.1038\/nrneph.2016.164"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00467-012-2103-2","article-title":"Genetic disorders of phosphate regulation","volume":"27","author":"Gattineni","year":"2012","journal-title":"Pediatr. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.kint.2017.11.036","article-title":"Prevention and treatment of hyperphosphatemia in chronic kidney disease","volume":"93","author":"Vervloet","year":"2018","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.01060308","article-title":"Consistent control of mineral and bone disorder in incident hemodialysis patients","volume":"3","author":"Danese","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/nure.12115","article-title":"Dietary educational interventions for management of hyperphosphatemia in hemodialysis patients: A systematic review and meta-analysis","volume":"72","author":"Karavetian","year":"2014","journal-title":"Nutr. Rev."},{"doi-asserted-by":"crossref","unstructured":"Ghimire, S., Castelino, R.L., Lioufas, N.M., Peterson, G.M., and Zaidi, S.T. (2015). Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review. PLoS ONE, 10.","key":"ref_10","DOI":"10.1371\/journal.pone.0144119"},{"doi-asserted-by":"crossref","unstructured":"Karamanidou, C., Clatworthy, J., Weinman, J., and Horne, R. (2008). A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol., 9.","key":"ref_11","DOI":"10.1186\/1471-2369-9-2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S29549","article-title":"Definitions, variants, and causes of nonadherence with medication: A challenge for tailored interventions","volume":"7","author":"Hugtenburg","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.bpj.2010.10.030","article-title":"Fetuin-A is a mineral carrier protein: Small angle neutron scattering provides new insight on Fetuin-A controlled calcification inhibition","volume":"99","author":"Heiss","year":"2010","journal-title":"Biophys. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1093\/nar\/gkg788","article-title":"The inflammation-induced down-regulation of plasma Fetuin-A (alpha2HS-Glycoprotein) in liver results from the loss of interaction between long C\/EBP isoforms at two neighbouring binding sites","volume":"31","author":"Gangneux","year":"2003","journal-title":"Nucleic Acids Res."},{"doi-asserted-by":"crossref","unstructured":"Smith, E.R., Hanssen, E., McMahon, L.P., and Holt, S.G. (2013). Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS ONE, 8.","key":"ref_15","DOI":"10.1371\/journal.pone.0060904"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.atherosclerosis.2016.05.044","article-title":"Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha","volume":"251","author":"Aghagolzadeh","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_17","first-page":"1957","article-title":"Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD","volume":"27","author":"Smith","year":"2012","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(03)12710-9","article-title":"Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study","volume":"361","author":"Ketteler","year":"2003","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1681\/ASN.2009090944","article-title":"Fetuin-mineral complex reflects extraosseous calcification stress in CKD","volume":"21","author":"Hamano","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","first-page":"1583","article-title":"Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease","volume":"31","author":"Holt","year":"2016","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1681\/ASN.2012030240","article-title":"Nanoparticle-based test measures overall propensity for calcification in serum","volume":"23","author":"Pasch","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1681\/ASN.2014070670","article-title":"Calcification Propensity and Survival among Renal Transplant Recipients","volume":"27","author":"Keyzer","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"doi-asserted-by":"crossref","unstructured":"Pasch, A., Block, G.A., Bachtler, M., Smith, E.R., Jahnen-Dechent, W., Arampatzis, S., Chertow, G.M., Parfrey, P., Ma, X., and Floege, J. (2016). Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clin. J. Am. Soc. Nephrol.","key":"ref_23","DOI":"10.2215\/CJN.04720416"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1681\/ASN.2013060635","article-title":"Serum calcification propensity predicts all-cause mortality in predialysis CKD","volume":"25","author":"Smith","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MNH.0000000000000237","article-title":"Novel assessments of systemic calcification propensity","volume":"25","author":"Pasch","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_26","first-page":"1","article-title":"Calciprotein particle (CPP): A true culprit of phosphorus woes?","volume":"34","year":"2014","journal-title":"Nefrologia"},{"doi-asserted-by":"crossref","unstructured":"Vervloet, M. (2018). Renal and extrarenal effects of fibroblast growth factor 23. Nat. Rev. Nephrol.","key":"ref_27","DOI":"10.1038\/s41581-018-0087-2"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1681\/ASN.2011101006","article-title":"Calcium deficiency reduces circulating levels of FGF23","volume":"23","author":"Lopez","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.kint.2016.01.024","article-title":"Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease","volume":"90","author":"Panizo","year":"2016","journal-title":"Kidney Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2215\/CJN.04730510","article-title":"Effects of dietary phosphate and calcium intake on fibroblast growth factor-23","volume":"6","author":"Vervloet","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2009121293","article-title":"Forging forward with 10 burning questions on FGF23 in kidney disease","volume":"21","author":"Wolf","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13591","DOI":"10.14814\/phy2.13591","article-title":"High Fibroblast Growth Factor 23 concentrations in experimental renal failure impair calcium handling in cardiomyocytes","volume":"6","author":"Verkaik","year":"2018","journal-title":"Physiol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kint.2018.03.024","article-title":"FGF23 effects on the heart-levels, time, source, and context matter","volume":"94","author":"Faul","year":"2018","journal-title":"Kidney Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab Therapy in Children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J. Bone Min. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000371454","article-title":"Hyperphosphate-Induced Myocardial Hypertrophy through the GATA-4\/NFAT-3 Signaling Pathway Is Attenuated by ERK Inhibitor Treatment","volume":"5","author":"Liu","year":"2015","journal-title":"Cardiorenal Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ki.2013.3","article-title":"Fibroblast growth factor 23 is not associated with and does not induce arterial calcification","volume":"83","author":"Scialla","year":"2013","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast Growth Factor-23 and Cardiovascular Events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"doi-asserted-by":"crossref","unstructured":"Verkaik, M., Juni, R.P., van Loon, E.P.M., van Poelgeest, E., Kwekkeboom, R.F.J., Gam, Z., Richards, W.G., Ter Wee, P.M., Hoenderop, J.G.J., and Eringa, E.C. (2018). FGF23 impairs peripheral microvascular function in renal failure. Am. J. Physiol. Heart Circ. Physiol.","key":"ref_44","DOI":"10.1152\/ajpheart.00272.2018"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","article-title":"FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability","volume":"307","author":"Silswal","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/cvr\/cvs240","article-title":"Effects of phosphate on vascular function under normal conditions and influence of the uraemic state","volume":"96","author":"Six","year":"2012","journal-title":"Cardiovasc. Res."},{"doi-asserted-by":"crossref","unstructured":"Rangrez, A.Y., M\u2019Baya-Moutoula, E., Metzinger-Le Meuth, V., Henaut, L., Djelouat, M.S., Benchitrit, J., Massy, Z.A., and Metzinger, L. (2012). Inorganic phosphate accelerates the migration of vascular smooth muscle cells: Evidence for the involvement of miR-223. PLoS ONE, 7.","key":"ref_47","DOI":"10.1371\/journal.pone.0047807"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1253\/circj.CJ-14-0735","article-title":"Vascular toxicity of phosphate in chronic kidney disease: Beyond vascular calcification","volume":"78","author":"Gross","year":"2014","journal-title":"Circ. J."},{"key":"ref_49","first-page":"2028","article-title":"Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD","volume":"29","author":"Reuter","year":"2014","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ki.2013.327","article-title":"Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis","volume":"85","author":"Sakaguchi","year":"2014","journal-title":"Kidney Int."},{"doi-asserted-by":"crossref","unstructured":"De Roij van Zuijdewijn, C.L., Grooteman, M.P., Bots, M.L., Blankestijn, P.J., Steppan, S., Buchel, J., Groenwold, R.H., Brandenburg, V., van den Dorpel, M.A., and Ter Wee, P.M. (2015). Serum Magnesium and Sudden Death in European Hemodialysis Patients. PLoS ONE, 10.","key":"ref_51","DOI":"10.1371\/journal.pone.0143104"},{"doi-asserted-by":"crossref","unstructured":"Leenders, N.H.J., and Vervloet, M.G. (2019). Magnesium: A Magic Bullet for Cardiovascular Disease in Chronic Kidney Disease?. Nutrients, 11.","key":"ref_52","DOI":"10.3390\/nu11020455"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e116273","DOI":"10.1371\/journal.pone.0116273","article-title":"Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: A cohort study","volume":"9","author":"Sakaguchi","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11255-019-02073-w","article-title":"Hypomagnesemia is not an independent risk factor for mortality in Japanese maintenance hemodialysis patients","volume":"51","author":"Mizuiri","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2018111150","article-title":"A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD","volume":"30","author":"Sakaguchi","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3945\/ajcn.116.131466","article-title":"Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: Results of a randomized, double-blind, placebo-controlled intervention trial","volume":"103","author":"Joris","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1097\/01.ASN.0000081663.52165.66","article-title":"Vascular calcification: In vitro evidence for the role of inorganic phosphate","volume":"14","author":"Giachelli","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ. Res."},{"key":"ref_59","first-page":"869","article-title":"Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells","volume":"28","author":"Louvet","year":"2013","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"doi-asserted-by":"crossref","unstructured":"Montes de Oca, A., Guerrero, F., Martinez-Moreno, J.M., Madueno, J.A., Herencia, C., Peralta, A., Almaden, Y., Lopez, I., Aguilera-Tejero, E., and Gundlach, K. (2014). Magnesium inhibits Wnt\/beta-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS ONE, 9.","key":"ref_60","DOI":"10.1371\/journal.pone.0089525"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0003-9969(75)90057-6","article-title":"Growth of calcium phosphates on hydroxyapatite crystals: The effect of magnesium","volume":"20","author":"Tomazic","year":"1975","journal-title":"Arch. Oral Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1038\/s41598-018-20241-3","article-title":"Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation","volume":"8","author":"Tinnemans","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ekir.2016.12.008","article-title":"Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial","volume":"2","author":"Bressendorff","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2215\/CJN.13921217","article-title":"The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial","volume":"13","author":"Bressendorff","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.kint.2017.04.011","article-title":"Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats","volume":"92","author":"Raya","year":"2017","journal-title":"Kidney Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1684\/mrh.2016.0412","article-title":"Magnesium-based interventions for normal kidney function and chronic kidney disease","volume":"29","author":"Massy","year":"2016","journal-title":"Magnes. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIRCRESAHA.110.238808","article-title":"Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization","volume":"109","author":"Kapustin","year":"2011","journal-title":"Circ. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circ. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/CIRCRESAHA.108.181305","article-title":"Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: A potential mechanism in atherosclerotic plaque destabilization","volume":"103","author":"Ewence","year":"2008","journal-title":"Circ. Res."},{"key":"ref_70","first-page":"999","article-title":"Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: A randomized, open-labeled clinical trial","volume":"13","author":"Han","year":"2017","journal-title":"Clin. Risk Manag."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bone.2017.03.043","article-title":"Tissue expression and source of circulating alphaKlotho","volume":"100","author":"Olauson","year":"2017","journal-title":"Bone"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.2008070783","article-title":"Initial FGF23-mediated signaling occurs in the distal convoluted tubule","volume":"20","author":"Farrow","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature25451","article-title":"alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling","volume":"553","author":"Chen","year":"2018","journal-title":"Nature"},{"doi-asserted-by":"crossref","unstructured":"Hum, J.M., O\u2019Bryan, L.M., Tatiparthi, A.K., Cass, T.A., Clinkenbeard, E.L., Cramer, M.S., Bhaskaran, M., Johnson, R.L., Wilson, J.M., and Smith, R.C. (2016). Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. J. Am. Soc. Nephrol.","key":"ref_77","DOI":"10.1681\/ASN.2015111266"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.semnephrol.2012.12.013","article-title":"Renal and extrarenal actions of Klotho","volume":"33","author":"Hu","year":"2013","journal-title":"Semin. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1681\/ASN.2014101030","article-title":"Renal Production, Uptake, and Handling of Circulating alphaKlotho","volume":"27","author":"Hu","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.3195","article-title":"Klotho Lacks an FGF23-Independent Role in Mineral Homeostasis","volume":"32","author":"Andrukhova","year":"2017","journal-title":"J. Bone Min. Res."},{"doi-asserted-by":"crossref","unstructured":"Sakan, H., Nakatani, K., Asai, O., Imura, A., Tanaka, T., Yoshimoto, S., Iwamoto, N., Kurumatani, N., Iwano, M., and Nabeshima, Y. (2014). Reduced renal alpha-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS ONE, 9.","key":"ref_81","DOI":"10.1371\/journal.pone.0086301"},{"key":"ref_82","first-page":"223","article-title":"The demonstration of alphaKlotho deficiency in human chronic kidney disease with a novel synthetic antibody","volume":"30","author":"Barker","year":"2015","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ki.2011.461","article-title":"KLOTHO methylation is linked to uremic toxins and chronic kidney disease","volume":"81","author":"Young","year":"2012","journal-title":"Kidney Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.semnephrol.2014.09.003","article-title":"The role of klotho on vascular calcification and endothelial function in chronic kidney disease","volume":"34","author":"Vervloet","year":"2014","journal-title":"Semin. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCGENETICS.108.847814","article-title":"In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels","volume":"2","author":"Ohnishi","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1096\/fj.09-152488","article-title":"Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging","volume":"24","author":"Ohnishi","year":"2010","journal-title":"FASEB J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1681\/ASN.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease","volume":"22","author":"Hu","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"doi-asserted-by":"crossref","unstructured":"Kawai, M., Kinoshita, S., Ozono, K., and Michigami, T. (2016). Inorganic Phosphate Activates the AKT\/mTORC1 Pathway and Shortens the Life Span of an alphaKlotho-Deficient Model. J. Am. Soc. Nephrol.","key":"ref_88","DOI":"10.1681\/ASN.2015040446"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1681\/ASN.2017121254","article-title":"A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects","volume":"29","author":"Mohammad","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"19308","DOI":"10.1073\/pnas.1008544107","article-title":"Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity","volume":"107","author":"Kusaba","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","first-page":"2968","article-title":"Aortic valve calcification in chronic kidney disease","volume":"28","author":"Rattazzi","year":"2013","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00109-017-1527-3","article-title":"Klotho suppresses high phosphate-induced osteogenic responses in human aortic valve interstitial cells through inhibition of Sox9","volume":"95","author":"Li","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ncomms2240","article-title":"Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart","volume":"3","author":"Xie","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1681\/ASN.2014040325","article-title":"Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate","volume":"26","author":"Xie","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1160\/TH08-02-0087","article-title":"Matrix Gla-protein: The calcification inhibitor in need of vitamin K","volume":"100","author":"Schurgers","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_96","first-page":"31","article-title":"Vascular calcification in chronic kidney disease: An update","volume":"31","author":"Schlieper","year":"2016","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"doi-asserted-by":"crossref","unstructured":"Wasilewski, G.B., Vervloet, M.G., and Schurgers, L.J. (2019). The Bone\u2014Vasculature Axis: Calcium Supplementation and the Role of Vitamin K. Front. Cardiovasc. Med., 6.","key":"ref_97","DOI":"10.3389\/fcvm.2019.00006"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000124863","article-title":"The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification","volume":"45","author":"Cranenburg","year":"2008","journal-title":"J. Vasc. Res."},{"doi-asserted-by":"crossref","unstructured":"Han, K.H., and O\u2019Neill, W.C. (2016). Increased Peripheral Arterial Calcification in Patients Receiving Warfarin. J. Am. Heart Assoc., 5.","key":"ref_99","DOI":"10.1161\/JAHA.115.002665"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1681\/ASN.2016060651","article-title":"Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis","volume":"28","author":"Nigwekar","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2215\/CJN.07081009","article-title":"The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report","volume":"5","author":"Schurgers","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00075197-200011000-00004","article-title":"Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification","volume":"3","author":"Shearer","year":"2000","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/ATVBAHA.114.304392","article-title":"Increased vascular calcification in patients receiving warfarin","volume":"35","author":"Tantisattamo","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13668-017-0208-8","article-title":"The Role of Vitamin K Status in Cardiovascular Health: Evidence from Observational and Clinical Studies","volume":"6","author":"Beulens","year":"2017","journal-title":"Curr. Nutr. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ki.2009.126","article-title":"Vitamin K deficiency in CKD patients: A modifiable risk factor for vascular calcification?","volume":"76","author":"Krueger","year":"2009","journal-title":"Kidney Int."},{"key":"ref_106","first-page":"1633","article-title":"Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): A rationale and study protocol","volume":"29","author":"Krueger","year":"2014","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cca.2018.12.029","article-title":"Serum total matrix Gla protein: Reference interval in healthy adults and variations in patients with vascular and osteoarticular diseases","volume":"490","author":"Silaghi","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_108","first-page":"gin\/33.6.5","article-title":"The influence of phosphate, calcium and magnesium on matrix Gla-protein and vascular calcification: A systematic review","volume":"33","author":"Houben","year":"2016","journal-title":"G. Ital. Nefrol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/ATVBAHA.117.310578","article-title":"Chronic Kidney Disease Circulating Calciprotein Particles and Extracellular Vesicles Promote Vascular Calcification: A Role for GRP (Gla-Rich Protein)","volume":"38","author":"Viegas","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0162-0134(96)00080-3","article-title":"The influence of trace elements on calcium phosphate formation by matrix vesicles","volume":"65","author":"Sauer","year":"1997","journal-title":"J. Inorg. Biochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3746\/pnf.2013.18.2.092","article-title":"Phosphate-induced rat vascular smooth muscle cell calcification and the implication of zinc deficiency in a7r5 cell viability","volume":"18","author":"Shin","year":"2013","journal-title":"Prev. Nutr. Food Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1681\/ASN.2017050492","article-title":"Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF-kappaB","volume":"29","author":"Voelkl","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"doi-asserted-by":"crossref","unstructured":"Chen, W., Eisenberg, R., Mowrey, W.B., Wylie-Rosett, J., Abramowitz, M.K., Bushinsky, D.A., and Melamed, M.L. (2019). Association between dietary zinc intake and abdominal aortic calcification in US adults. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.","key":"ref_113","DOI":"10.1093\/ndt\/gfz134"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"F643","DOI":"10.1152\/ajprenal.00228.2007","article-title":"Phosphate transporters: A tale of two solute carrier families","volume":"293","author":"Virkki","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.RES.0000216409.20863.e7","article-title":"Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification","volume":"98","author":"Li","year":"2006","journal-title":"Circ. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1681\/ASN.2014030230","article-title":"NH4Cl Treatment Prevents Tissue Calcification in Klotho Deficiency","volume":"26","author":"Leibrock","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"F102","DOI":"10.1152\/ajprenal.00037.2015","article-title":"Bicarbonate-sensitive calcification and lifespan of klotho-deficient mice","volume":"310","author":"Leibrock","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/sj.ki.5002646","article-title":"Metabolic acidosis inhibits soft tissue calcification in uremic rats","volume":"73","author":"Mendoza","year":"2008","journal-title":"Kidney Int."},{"key":"ref_119","first-page":"267","article-title":"Correlation of coronary artery calcification with pre-hemodialysis bicarbonate levels in patients on hemodialysis","volume":"16","author":"Oka","year":"2012","journal-title":"Apher. Dial. Off. Peer-Rev. J. Int. Soc. Apher. Jpn. Soc. Apher. Jpn. Soc. Dial."},{"doi-asserted-by":"crossref","unstructured":"Lamina, C., Kronenberg, F., Stenvinkel, P., Froissart, M., Forer, L., Schonherr, S., Wheeler, D.C., Eckardt, K.U., and Floege, J. (2019). Association of changes in bone mineral parameters with mortality in haemodialysis patients: Insights from the ARO cohort. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.","key":"ref_120","DOI":"10.1093\/ndt\/gfz060"},{"key":"ref_121","first-page":"1207","article-title":"Functional impairment attenuates the association between high serum phosphate and mortality in dialysis patients: A nationwide cohort study","volume":"34","author":"Wakasugi","year":"2019","journal-title":"Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00198-015-3372-y","article-title":"Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: Secondary analysis of a randomized controlled trial","volume":"27","author":"Bristow","year":"2016","journal-title":"Osteoporos. Int."},{"doi-asserted-by":"crossref","unstructured":"Dekker, M., Pasch, A., van der Sande, F., Konings, C., Bachtler, M., Dionisi, M., Meier, M., Kooman, J., and Canaud, B. (2016). High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity. PLoS ONE, 11.","key":"ref_123","DOI":"10.1371\/journal.pone.0151508"},{"doi-asserted-by":"crossref","unstructured":"Ketteler, M., Sprague, S.M., Covic, A.C., Rastogi, A., Spinowitz, B., Rakov, V., Walpen, S., and Floege, J. (2018). Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.","key":"ref_124","DOI":"10.1093\/ndt\/gfy127"},{"doi-asserted-by":"crossref","unstructured":"Rodelo-Haad, C., Rodriguez-Ortiz, M.E., Martin-Malo, A., Pendon-Ruiz de Mier, M.V., Aguera, M.L., Munoz-Castaneda, J.R., Soriano, S., Caravaca, F., Alvarez-Lara, M.A., and Felsenfeld, A. (2018). Phosphate control in reducing FGF23 levels in hemodialysis patients. PLoS ONE, 13.","key":"ref_125","DOI":"10.1371\/journal.pone.0201537"},{"doi-asserted-by":"crossref","unstructured":"David, V., Martin, A., Isakova, T., Spaulding, C., Qi, L., Ramirez, V., Zumbrennen-Bullough, K.B., Sun, C.C., Lin, H.Y., and Babitt, J.L. (2015). Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int.","key":"ref_126","DOI":"10.1038\/ki.2015.290"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"doi-asserted-by":"crossref","unstructured":"Sakaguchi, Y., Hamano, T., Matsui, I., Oka, T., Yamaguchi, S., Kubota, K., Shimada, K., Matsumoto, A., Hashimoto, N., and Isaka, Y. (2018). Low magnesium diet aggravates phosphate-induced kidney injury. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.","key":"ref_128","DOI":"10.1093\/ndt\/gfy358"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"10256","DOI":"10.1038\/s41598-018-28629-x","article-title":"Routine hemodialysis induces a decline in plasma magnesium concentration in most patients: A prospective observational cohort study","volume":"8","author":"Leenders","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e016795","DOI":"10.1136\/bmjopen-2017-016795","article-title":"The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): Essential study design and rationale","volume":"7","author":"Bressendorff","year":"2017","journal-title":"BMJ Open"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"34597","DOI":"10.1038\/srep34597","article-title":"Rhein reversal of DNA hypermethylation-associated Klotho suppression ameliorates renal fibrosis in mice","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"46745","DOI":"10.18632\/oncotarget.18608","article-title":"Induction of anti-aging gene klotho with a small chemical compound that demethylates CpG islands","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1038\/s41467-018-07253-3","article-title":"Age-related declines in alpha-Klotho drive progenitor cell mitochondrial dysfunction and impaired muscle regeneration","volume":"9","author":"Sahu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ki.2012.322","article-title":"Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet","volume":"82","author":"Lau","year":"2012","journal-title":"Kidney Int."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1097\/TP.0000000000001339","article-title":"Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients","volume":"100","year":"2016","journal-title":"Transplantation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1160\/TH08-04-0241","article-title":"Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients","volume":"101","author":"Cranenburg","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3945\/ajcn.2008.27338","article-title":"Vitamin K supplementation and progression of coronary artery calcium in older men and women","volume":"89","author":"Shea","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.116.027011","article-title":"Slower Progress of Aortic Valve Calcification with Vitamin K Supplementation: Results from a Prospective Interventional Proof-of-Concept Study","volume":"135","author":"Brandenburg","year":"2017","journal-title":"Circulation"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ckj\/sfv146","article-title":"The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: Ongoing randomized controlled trials","volume":"9","author":"Caluwe","year":"2016","journal-title":"Clin. Kidney J."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/9\/522\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:17:55Z","timestamp":1760188675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/11\/9\/522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":139,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["toxins11090522"],"URL":"https:\/\/doi.org\/10.3390\/toxins11090522","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2019,9,9]]}}}